Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dose to specific subregions of pelvic bone marrow defined with FDG-PET as a predictor of hematologic nadirs during concomitant chemoradiation in anal cancer patients.
Franco P, Arcadipane F, Ragona R, Lesca A, Gallio E, Mistrangelo M, Cassoni P, Arena V, Bustreo S, Faletti R, Rondi N, Morino M, Ricardi U. Franco P, et al. Among authors: bustreo s. Med Oncol. 2016 Jul;33(7):72. doi: 10.1007/s12032-016-0789-x. Epub 2016 Jun 8. Med Oncol. 2016. PMID: 27277756
Concomitant adjuvant chemoradiotherapy with weekly low-dose cisplatin for high-risk squamous cell carcinoma of the head and neck: a phase II prospective trial.
Rampino M, Ricardi U, Munoz F, Reali A, Barone C, Musu AR, Balcet V, Franco P, Grillo R, Bustreo S, Pecorari G, Cavalot A, Garzino Demo P, Ciuffreda L, Ragona R, Schena M. Rampino M, et al. Among authors: bustreo s. Clin Oncol (R Coll Radiol). 2011 Mar;23(2):134-40. doi: 10.1016/j.clon.2010.09.004. Epub 2010 Oct 27. Clin Oncol (R Coll Radiol). 2011. PMID: 21030225 Free article. Clinical Trial.
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials.
Fucà G, Guarini V, Antoniotti C, Morano F, Moretto R, Corallo S, Marmorino F, Lonardi S, Rimassa L, Sartore-Bianchi A, Borelli B, Tampellini M, Bustreo S, Claravezza M, Boccaccino A, Murialdo R, Zaniboni A, Tomasello G, Loupakis F, Adamo V, Tonini G, Cortesi E, de Braud F, Cremolini C, Pietrantonio F. Fucà G, et al. Among authors: bustreo s. Br J Cancer. 2020 Aug;123(3):403-409. doi: 10.1038/s41416-020-0894-7. Epub 2020 May 19. Br J Cancer. 2020. PMID: 32424148 Free PMC article.
FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.
Cremolini C, Loupakis F, Masi G, Lonardi S, Granetto C, Mancini ML, Chiara S, Moretto R, Rossini D, Vitello S, Allegrini G, Tonini G, Bergamo F, Tomasello G, Ronzoni M, Buonadonna A, Bustreo S, Barbara C, Boni L, Falcone A. Cremolini C, et al. Among authors: bustreo s. Ann Oncol. 2016 May;27(5):843-9. doi: 10.1093/annonc/mdw052. Epub 2016 Feb 9. Ann Oncol. 2016. PMID: 26861604 Free article. Clinical Trial.
DNA repair gene expression level in peripheral blood and tumour tissue from non-small cell lung cancer and head and neck squamous cell cancer patients.
Schena M, Guarrera S, Buffoni L, Salvadori A, Voglino F, Allione A, Pecorari G, Ruffini E, Garzino-Demo P, Bustreo S, Consito L, Bironzo P, Matullo G. Schena M, et al. Among authors: bustreo s. DNA Repair (Amst). 2012 Apr 1;11(4):374-80. doi: 10.1016/j.dnarep.2012.01.003. Epub 2012 Jan 28. DNA Repair (Amst). 2012. PMID: 22284908
Chimeric rat/human HER2 efficiently circumvents HER2 tolerance in cancer patients.
Occhipinti S, Sponton L, Rolla S, Caorsi C, Novarino A, Donadio M, Bustreo S, Satolli MA, Pecchioni C, Marchini C, Amici A, Cavallo F, Cappello P, Pierobon D, Novelli F, Giovarelli M. Occhipinti S, et al. Among authors: bustreo s. Clin Cancer Res. 2014 Jun 1;20(11):2910-21. doi: 10.1158/1078-0432.CCR-13-2663. Epub 2014 Mar 25. Clin Cancer Res. 2014. PMID: 24668647 Free article.
Phase II Study of Preoperative Treatment with External Radiotherapy Plus Panitumumab in Low-Risk, Locally Advanced Rectal Cancer (RaP Study/STAR-03).
Pinto C, Di Bisceglie M, Di Fabio F, Bochicchio A, Latiano T, Cordio S, Rosati G, Aschele C, Marino A, Bergamo F, Bustreo S, Frassineti L, Ciardiello F, Damato A, Giaquinta S, Baldari D, Boni L. Pinto C, et al. Among authors: bustreo s. Oncologist. 2018 Aug;23(8):912-918. doi: 10.1634/theoncologist.2017-0484. Epub 2018 Mar 9. Oncologist. 2018. PMID: 29523646 Free PMC article. Clinical Trial.
15 results